The Nasopharyngeal Cancer market is expected to witness a steady CAGR of 2.8% during the forecast period.
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. Radiation therapy forms the primary modality of treatment in nasopharyngeal cancer. It is closely followed by chemotherapy in terms of both market share and use-case in patients. Newer and advanced modalities of nasopharyngeal cancer treatment include a combination of both radiotherapy and chemotherapy techniques. The most common presenting sign of NPC is unilateral neck mass (approximately 80% cases.
Major Players in the market are Roche, Sanofi, Merck, Cyclacel Pharmaceuticals, Celgene, BioDiem Ambrx Inc., arGEN-X BV and Atara Biotherapeutics Inc.
A research team led by Hong Kong Baptist University (HKBU) in 2020 has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus. It is the first known agent to successfully target the virus and disturb its latency in tumor cells in this way. The strategy of reactivation of EBV from its latency is a new trend in nasopharyngeal carcinoma (NPC) therapy, and some non-specific, anti-viral drugs have recently entered phase one or phase two clinical trials. Our new drug represents the first specific targeted agent to disrupt a single viral protein and to potently reactivate EBV from its latency.
March 2020 – Roche announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the cobas SARS-CoV-2 Test. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria for testing. Hospitals and reference laboratories can run the test on Roche’s fully automated cobas 6800 and cobas 8800 Systems, which are widely available in the U.S. and around the world.
According to study result published in Cancer. Aug 2020, an induction –concurrent chemotherapy sequences conferred a PFS benefit for patients with loco regionally advanced nasopharyngeal carcinoma treated with conventional fractioned radiotherapy.
Market segmentation is classified in the basis of type of treatment, end user and region. Based on end-user, the global nasopharyngeal cancer treatment market can be divided into hospitals, clinics, and cancer treatment & rehabilitation centers. By Treatment Type it has included Radiation Therapy, Chemotherapy and Surgery. In terms of region, the global nasopharyngeal cancer treatment market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Southeast Asia including Indonesia is the area with high prevalence of NPC cases.